糖皮质激素辅助治疗肺炎支原体大叶性肺炎患儿的临床疗效观察被引量：6

下载PDF

导出

摘要目的:分析糖皮质激素辅助治疗肺炎支原体大叶性肺炎患儿的临床效果。方法:选取36例肺炎支原体大叶性肺炎患儿为研究对象。通过随机分组法,将其分为参照组和试验组,每组18例。参照组患儿进行常规治疗,试验组患儿实施常规治疗加糖皮质激素(地塞米松)辅助治疗,将两组患儿临床症状及体征改善时间、治疗前后的肺功能[用力肺活量(FVC)、呼气峰流速(PEF)、第1秒用力呼气量(FEV1)]进行对比分析。结果:治疗后,试验组患儿的退热时间、咳嗽消失时间、胸片恢复正常时间、肺部啰音消失时间均短于参照组,差异有统计学意义(P<0.05);两组患者的肺功能指标均较治疗前改善,其中试验组患儿的FVC、PEF、FEV1均高于参照组,差异有统计学意义(P<0.05)。结论:针对肺炎支原体大叶性肺炎患儿,使用糖皮质激素辅助治疗改善其肺功能,值得推广应用。

作者冒晓飚

机构地区如皋市人民医院药剂科

出处《吉林医学》 CAS 2018年第7期1293-1294,共2页 Jilin Medical Journal

关键词肺炎支原体糖皮质激素大叶性肺炎

分类号 R725.6 [医药卫生—儿科]

引文网络
相关文献

参考文献6

1倪凯华,赵建美,肖钦志,张晓群.糖皮质激素对大叶性肺炎患儿血清TNF-α、IL-6、IL-8水平的影响[J].现代生物医学进展,2015,15(23):4512-4514. 被引量：14
2刘青,李虎,张玲,华亚军.糖皮质激素辅助治疗儿童难治性肺炎支原体肺炎的临床疗效[J].儿科药学杂志,2016,22(8):25-27. 被引量：21
3刘佳.糖皮质激素对肺炎支原体大叶性肺炎患儿肺功能及CRP、ESR、IL-2、IL-6的影响[J].当代医学,2017,23(2):58-59. 被引量：11
4查琳.儿童支原体感染相关性大叶性肺炎的临床治疗[J].中国妇幼保健,2015,30(15):2381-2383. 被引量：21
5吴海飞,檀卫平,黄花荣,吴葆菁,韩明珊,欧榕琼.糖皮质激素在儿童重症或难治性肺炎支原体肺炎治疗中的价值[J].新医学,2015,46(8):535-538. 被引量：16
6姚欢银,张佩红,童海明,刘伟荣,刘淑梅,陈啸洪.血清糖皮质激素受体在难治性肺炎支原体肺炎患儿中的变化及临床意义[J].医学研究杂志,2016,45(10):82-85. 被引量：6

二级参考文献41

1Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE, Cousens S, Mathers C, Black RE. Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet, 2015, 385 ( 9966 ) : 430-440.
2Shin JE, Cheon BR, Shim JW, Kim DS, Jung HL, Park MS, Shim JY. Increased risk of refractory Myco- plasma pneumoniae pneumonia in children with atopie sensitization and asthma. Korean J Pediatr, 2014, 57 (6) : 271-277.
3You SY, Jwa H J, Yang EA, Kil HR, Lee JH. Effects of methylprednisolone pulse therapy on refractory myco- plasma pneumoniae pneumonia in children. Allergy Asthma Immunol Res, 2014, 6 (1) : 22-26.
4Inamura N, Miyashita N, Hasegawa S, Kato A, Fukuda Y, Saitoh A, Kondo E, Teranishi H, Wakabayashi T, Akaike H, Tanaka T, Ogita S, Nakano T, Terada K, Ouchi K. Management of refractory Mycoplasma pneu- moniae pneumonia: utility of measuring serum lactate dehydrogenase level. J Infect Chemother, 2014, 20 (4) : 270-273.
5Lai JF, Zindl CL, Duffy LB, Atkinson TP, Jung YW, van Rooijen N, Waites KB, Krause DC, Chaplin DD. Critical role of macrophages and their activation via MyD88-NFKB signaling in lung innate immunity to My- coplasma pneumoniae. PLoS One, 2010, 5 ( 12 ) : e14417.
6Kurata S, Osaki T, Yonezawa H, Arae K, Taguchi H, Kamiya S. Role IL-17A and IL-10 in the antigen in- duced inflammation model by mycoplasma pneumoniae. BMC Microbiol, 2014, 14: 156.
7Medina JL, Coalson JJ, Brooks EG, Winter VT, Chap- arro A, Principe MF, Kannan TR, Baseman JB, Dube PH. Mycoplasma pneumoniae CARDS toxin induces pul- monary eosinophilic and lymphocytic inflammation. Am J Respir Cell Mol Biol, 2012, 46 (6) : 815-822.
8Oishi T, Narita M, Matsui K, Shirai T, Matsuo M, Negishi J, Kaneko T, Tsukano S, Taguchi T, Uchiyama M. Clinical implications of interleukin-18 levels in pedi- atric patients with mycoplasma pneumoniae pneumonia. J Infect Chemother, 2011, 17 (6) : 803-806.
9Narita M. Pathogenesis of extrapulmonary manifestations of Mycoplasma pneumoniae infection with special refer- ence to pneumonia. J Infect Chemother, 2010, 16 (3) : 162-169.
10Youn YS, Lee SC, Rhim JW, Shin MS, Kang JH, Lee KY. Early additional immune-modulators for mycoplas- ma pneumoniae pneumonia in children: an observation study. Infect Chemother, 2014, 46 (4) : 239-247.